ArticleInfection and drug resistance2008
Current and novel antibiotics against resistant Gram-positive bacteria.
Article in Infection and drug resistance, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-ResistantMicroorganisms · 2026Review
- Permeabilize, but Choose Wisely: Selective Antibiotic Potentiation Through Outer Membrane Disruption inInternational journal of molecular sciences · 2025Article
- Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.Clinical pharmacokinetics · 2021Review
- First Case of Staphylococci Carrying Linezolid Resistance Genes from Laryngological Infections in Poland.Pathogens (Basel, Switzerland) · 2021Article
- The Continuing Threat of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2019Review
- Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance.mBio · 2018Article
- Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range.Infection and drug resistance · 2016Article
- Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Article
- Orthosiphon stamineus protects Caenorhabditis elegans against Staphylococcus aureus infection through immunomodulation.Biology open · 2014Article
- [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Biomedica : revista del Instituto Nacional de Salud · 2014Review
- Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound pathogens.The open microbiology journal · 2014Article
- rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.Antimicrobial agents and chemotherapy · 2012Article
- In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.